**Core Concept**
Extended spectrum beta-lactamases (ESBLs) are a type of β-lactamase enzyme that confers resistance to a broader spectrum of β-lactam antibiotics, including penicillins, cephalosporins, and aztreonam, but not carbapenems. This resistance mechanism is mediated through the hydrolysis of the β-lactam ring, rendering the antibiotic ineffective against bacterial infections.

**Why the Correct Answer is Right**
ESBLs are produced by certain Gram-negative bacteria, such as *Escherichia coli* and *Klebsiella pneumoniae*, as a mechanism of defense against β-lactam antibiotics. These enzymes are capable of hydrolyzing the β-lactam ring of antibiotics, including third-generation cephalosporins, which are typically resistant to earlier β-lactamases. The presence of ESBLs is often detected through laboratory tests, such as the double-disk synergy test or the Etest.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because ESBLs do not confer resistance to carbapenems, which are a class of broad-spectrum β-lactam antibiotics that are typically resistant to β-lactamases.
**Option B:** This option is incorrect because ESBLs are not specific to Gram-positive bacteria, but rather are produced by certain Gram-negative bacteria.
**Option C:** This option is incorrect because ESBLs are not a type of antibiotic, but rather a type of enzyme that confers resistance to β-lactam antibiotics.

**Clinical Pearl / High-Yield Fact**
When suspecting an ESBL-producing infection, it is essential to use laboratory tests to confirm the presence of ESBLs, and to avoid using β-lactam antibiotics that are likely to be ineffective against these infections.

**Correct Answer: A.**